跳至主要内容
临床试验/NCT07493421
NCT07493421招募中不适用

Cytoreductive Surgery and HIPEC for Pancreatic Cancer With Peritoneal Metastasis - IGNIS Trial

Unidade Local de Saúde São João3 个研究点 分布在 2 个国家目标入组 20 人开始时间: 2026年3月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
20
试验地点
3
主要终点
Mortality

研究概览

简要总结

The goal of this clinical trial is to evaluate the safety and feasibility of a combined surgical and chemotherapy approach (pancreatectomy with cytoreductive surgery and HIPEC) in patients aged 18 and older with pancreatic ductal adenocarcinoma and synchronous peritoneal metastases. The main questions it aims to answer are:

Is the 90-day mortality rate for this intensive combined procedure lower than 5%? What are the postoperative morbidity and complication rates (as measured by the Clavien-Dindo classification) for these patients? How does this treatment impact the patient's quality of life 12 months after the procedure?

Participants will:

Complete at least 6 months of systemic chemotherapy to ensure the disease is stable or responding (biomarker CA19-9 must decline by >20%).

Undergo a major surgical procedure involving the removal of the pancreatic tumour (total Pancreatectomy or RAMPS) and any visible abdominal metastases (Cytoreductive Surgery).

Receive Hyperthermic Intraperitoneal Chemotherapy (HIPEC), where heated Cisplatin and Paclitaxel are circulated in the abdominal cavity for 90 minutes during the operation.

Participate in long-term follow-up to monitor recurrence-free and overall survival.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Pancreatic adenocarcinoma
  • Histologically confirmed peritoneal metastasis
  • Excluded other sites of metastasis (except ovary)
  • PCI less than or equal to 6
  • Age > 18 years
  • ECOG performance status 0-1
  • Written informed consent

排除标准

  • Pregnancy
  • Intestinal obstruction
  • Renal insufficiency (GFR < 45 ml/min)

结局指标

主要结局

Mortality

时间窗: In-hospital or 90 days after surgery

Measurement of postoperative mortality will be recorded

Morbidity

时间窗: In-hospital or 90 days after surgery

Post-operative morbidity will be recorded and classified according to Clavien-Dindo classification

次要结局

  • Quality of Life after the Procedure(12 months post-surgery)
  • Recurrence-Free Survival(12 months from surgery)
  • Overall Survival(12 months from surgery)

研究者

发起方
Unidade Local de Saúde São João
申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Tiago Bouça-Machado

MD

Unidade Local de Saúde São João

研究点 (3)

Loading locations...

相似试验